Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2021.28204
Abstract: Importance Tourette syndrome is a neurodevelopmental disorder characterized by childhood onset of motor and phonic tics; treatments for tics are associated with safety concerns. Deutetrabenazine is a selective vesicular monoamine transporter 2 inhibitor approved for… read more here.
Keywords: trial; safety; children adolescents; deutetrabenazine ... See more keywords
Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration‐QTc Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1161
Abstract: Deutetrabenazine (Austedo) is indicated in adults for chorea associated with Huntington disease and tardive dyskinesia. Escalating deutetrabenazine doses were administered to healthy volunteers who were cytochrome P450 2D6 extensive/intermediate metabolizers (EMs) or poor metabolizers (PMs)… read more here.
Keywords: evaluation; qtc analysis; deutetrabenazine; using concentration ... See more keywords
The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of clinical pharmacology"
DOI: 10.1007/s00228-021-03202-0
Abstract: PURPOSE Deutetrabenazine is a deuterated form of tetrabenazine with a confirmed lower rate of CYP2D6 metabolism of the active metabolites, α- and β-HTBZ. In this study, we assessed the effect of paroxetine, a potent CYP2D6… read more here.
Keywords: safety deutetrabenazine; safety; potent cyp2d6; effect ... See more keywords
Deutetrabenazine: A Review in Chorea Associated with Huntington’s Disease
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0831-0
Abstract: Oral deutetrabenazine (Austedo™), a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2) that is structurally related to tetrabenazine is approved for the treatment of chorea symptoms associated with Huntington’s disease (HD). In the pivotal… read more here.
Keywords: tetrabenazine; associated huntington; huntington disease; deutetrabenazine ... See more keywords
134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies
Sign Up to like & getrecommendations! Published in 2018 at "CNS Spectrums"
DOI: 10.1017/s1092852918000305
Abstract: Abstract Introduction Tardive dyskinesia (TD) is an involuntary movement disorder that is often irreversible, can affect any body region, and can be debilitating. In the ARM-TDand AIM-TD studies, deutetrabenazine treatment demonstrated statistically and clinically significant… read more here.
Keywords: aim; treatment; deutetrabenazine treatment; deutetrabenazine ... See more keywords
158 Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study
Sign Up to like & getrecommendations! Published in 2018 at "CNS Spectrums"
DOI: 10.1017/s1092852918000500
Abstract: Abstract Introduction In the 12-week ARM-TD and AIM-TD studies, deutetrabenazine showed clinically significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores at Week 12 compared with placebo, and was generally well tolerated. Objective To evaluate… read more here.
Keywords: week; term; long term; treatment ... See more keywords
34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities
Sign Up to like & getrecommendations! Published in 2019 at "CNS Spectrums"
DOI: 10.1017/s1092852919000282
Abstract: Abstract Background Tardive dyskinesia (TD) results from exposure to dopamine-receptor antagonists (DRAs), such as typical and atypical antipsychotics. Clinicians commonly manage TD by reducing the dose of or stopping the causative agent; however, this may… read more here.
Keywords: treatment; deutetrabenazine; long term; week ... See more keywords
Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington's Disease.
Sign Up to like & getrecommendations! Published in 2021 at "CNS spectrums"
DOI: 10.1017/s1092852920002618
Abstract: BACKGROUND In the First-HD pivotal trial, the maximum deutetrabenazine dose evaluated to treat chorea associated with Huntington's disease (HD chorea) was 48 mg/d, which is the approved maximum dose for this population. In ARC-HD, an… read more here.
Keywords: safety deutetrabenazine; huntington disease; deutetrabenazine; treat chorea ... See more keywords
Effects of Long-Term Deutetrabenazine Treatment in Patients with Tardive Dyskinesia and Underlying Psychiatric or Mood Disorders
Sign Up to like & getrecommendations! Published in 2022 at "CNS Spectrums"
DOI: 10.1017/s1092852922000554
Abstract: Abstract Introduction Deutetrabenazine is FDA-approved for the treatment of tardive dyskinesia (TD) in adults. In two 12-week pivotal trials (ARM-TD/AIM-TD), deutetrabenazine significantly improved Abnormal Involuntary Movement Scale (AIMS) scores and was well-tolerated. This post hoc… read more here.
Keywords: long term; term deutetrabenazine; deutetrabenazine; treatment ... See more keywords
Review of deutetrabenazine: a novel treatment for chorea associated with Huntington’s disease
Sign Up to like & getrecommendations! Published in 2018 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s138828
Abstract: Deutetrabenazine was recently approved for the treatment of chorea in Huntington’s disease (HD) and is the first deuterated medication that has been US Food and Drug Administration (FDA)-approved for therapeutic use. In this article, we… read more here.
Keywords: huntington disease; treatment; drug; deutetrabenazine ... See more keywords